Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Pharmacy | 7 | 2025 | 90 | 2.420 |
Why?
|
| Education, Pharmacy | 7 | 2025 | 123 | 2.070 |
Why?
|
| Problem-Based Learning | 4 | 2019 | 62 | 1.530 |
Why?
|
| Education, Medical | 2 | 2019 | 68 | 0.990 |
Why?
|
| Pharmacy | 2 | 2022 | 36 | 0.870 |
Why?
|
| Drug Compounding | 2 | 2021 | 32 | 0.650 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 67 | 0.600 |
Why?
|
| Curriculum | 6 | 2025 | 303 | 0.580 |
Why?
|
| Schools, Pharmacy | 3 | 2014 | 32 | 0.560 |
Why?
|
| Students | 1 | 2019 | 199 | 0.530 |
Why?
|
| Asepsis | 1 | 2015 | 1 | 0.490 |
Why?
|
| Drug Contamination | 1 | 2015 | 6 | 0.480 |
Why?
|
| Teaching | 1 | 2015 | 83 | 0.450 |
Why?
|
| Test Taking Skills | 1 | 2014 | 2 | 0.430 |
Why?
|
| Educational Measurement | 4 | 2025 | 131 | 0.380 |
Why?
|
| Internal Medicine | 1 | 2012 | 28 | 0.370 |
Why?
|
| Oklahoma | 6 | 2025 | 1052 | 0.320 |
Why?
|
| Program Evaluation | 4 | 2015 | 174 | 0.320 |
Why?
|
| Ergocalciferols | 1 | 2006 | 1 | 0.260 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2006 | 1 | 0.260 |
Why?
|
| Pharmaceutical Services | 2 | 2022 | 41 | 0.260 |
Why?
|
| Humans | 15 | 2025 | 28851 | 0.250 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 149 | 0.250 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 997 | 0.220 |
Why?
|
| Educational Status | 2 | 2015 | 112 | 0.220 |
Why?
|
| Preceptorship | 2 | 2016 | 22 | 0.220 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2025 | 44 | 0.220 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2022 | 24 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2015 | 235 | 0.190 |
Why?
|
| Judgment | 1 | 2021 | 31 | 0.180 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 78 | 0.170 |
Why?
|
| Perception | 2 | 2019 | 90 | 0.170 |
Why?
|
| Butanones | 1 | 2000 | 1 | 0.160 |
Why?
|
| Hemarthrosis | 1 | 2000 | 1 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2019 | 60 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2022 | 250 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 78 | 0.150 |
Why?
|
| Warfarin | 1 | 2000 | 94 | 0.150 |
Why?
|
| Students, Medical | 1 | 2019 | 102 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2000 | 297 | 0.140 |
Why?
|
| Lovastatin | 1 | 1997 | 6 | 0.130 |
Why?
|
| Anticholesteremic Agents | 1 | 1997 | 13 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 1997 | 18 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2010 | 215 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2016 | 18 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2014 | 222 | 0.120 |
Why?
|
| Program Development | 2 | 2012 | 87 | 0.110 |
Why?
|
| United States | 1 | 2019 | 2222 | 0.100 |
Why?
|
| Learning | 1 | 2014 | 100 | 0.100 |
Why?
|
| Volunteers | 1 | 2012 | 4 | 0.090 |
Why?
|
| Comprehension | 1 | 2012 | 19 | 0.090 |
Why?
|
| Accreditation | 1 | 2012 | 36 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 303 | 0.090 |
Why?
|
| Faculty | 1 | 2012 | 62 | 0.090 |
Why?
|
| Community Pharmacy Services | 1 | 2010 | 22 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 91 | 0.080 |
Why?
|
| Professional Role | 1 | 2009 | 46 | 0.070 |
Why?
|
| Pharmacists | 1 | 2009 | 74 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2006 | 24 | 0.060 |
Why?
|
| Quality of Life | 1 | 2009 | 521 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 40 | 0.050 |
Why?
|
| Adult | 2 | 2012 | 8024 | 0.050 |
Why?
|
| Aged | 3 | 2010 | 5598 | 0.050 |
Why?
|
| Assertiveness | 1 | 2021 | 4 | 0.050 |
Why?
|
| Empathy | 1 | 2021 | 39 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2000 | 79 | 0.040 |
Why?
|
| Communication | 1 | 2021 | 179 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 1997 | 58 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 1997 | 64 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 2426 | 0.030 |
Why?
|
| Triglycerides | 1 | 1997 | 123 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1997 | 224 | 0.030 |
Why?
|
| Male | 3 | 2010 | 13921 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2000 | 404 | 0.030 |
Why?
|
| Middle Aged | 2 | 2010 | 7414 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 11 | 0.020 |
Why?
|
| Quality Control | 1 | 2012 | 21 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 126 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1997 | 2635 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 91 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 631 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 995 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2065 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 2126 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2833 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 3193 | 0.010 |
Why?
|
| Female | 1 | 2010 | 15624 | 0.010 |
Why?
|